Ratings Elanco Animal Health Incorporated Deutsche Boerse AG

Equities

5EA

US28414H1032

Market Closed - Deutsche Boerse AG Other stock markets 02:05:10 2024-05-28 am EDT			5-day change	1st Jan Change
15.34 ^EUR	-0.13%		-1.29%	+16.02%

May. 28	US FDA approves Elanco's feed ingredient to cut methane emissions in dairy cows	RE
May. 28	Elanco Says FDA Confirms Bovaer Meets Safety, Efficacy Requirements	MT

Summary

Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For several months, analysts have been revising their EPS estimates roughly upwards.
Over the past four months, analysts' average price target has been revised upwards significantly.
Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

According to forecast, a sluggish sales growth is expected for the next fiscal years.
Low profitability weakens the company.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
ELANCO ANIMAL HEALTH INCORPORATED	+16.02%	8.3B	-
ZOETIS INC.	-13.21%	77.6B	B+
BLUESTAR ADISSEO COMPANY	+24.62%	3.72B	B-
VIRBAC	-2.09%	3.27B	B-
VIMIAN GROUP AB	+14.02%	1.65B	-
JINYU BIO-TECHNOLOGY CO., LTD.	-10.96%	1.56B	B
CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.	-24.54%	1.29B	C-
WUHAN KEQIAN BIOLOGY CO.,LTD	-15.65%	1.14B	-
TIANJIN RINGPU BIO-TECHNOLOGY CO.,LTD.	-5.25%	1.02B	-
PULIKE BIOLOGICAL ENGINEERING, INC.	-15.14%	985M	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes